Vasculitis Foundation Canada
AdvocacyOppose
Patient experience with avacopan
Patient quality of life
Patient safety and access
ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing
FDA-2026-N-1321-0001Notice
Comments
94
Last activity Jun 29, 2026
Deadline
Closed on Jun 30, 2026
Closed Jun 30, 2026
Net supportiSupport minus oppose · campaigns included
-54%
-54% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing
- Posted
- Apr 30, 2026
- Comment period
- Apr 30, 2026 – Jun 30, 2026
- FR Doc
- 2026-08455
- Topics
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Stance breakdown
-54%
Net support
Support19Oppose70Other5
Aggregates include form-letter campaigns. Excluding them, net support is -54% across organic comments.
Who commented
Breakdown by commenter type.
Business
2
Individual
88
Advocacy
4
Comments over time
Weekly arrivals, stacked by stance.
Posted Apr 30, 2026Deadline Jun 30, 2026
May 4May 18Jun 1Jun 15Jun 29
Support19Oppose70Other5
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Individual
20%
75%
5%
Advocacy
25%
50%
25%
Business
0%
100%
0%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Patient testimonial of efficacy24
Patient experience with tavneos18
Patient experience and efficacy17
Patient safety and efficacy14
Patient experience with avacopan12
Retain drug market availability10
Patient quality of life7
Patient safety and access5
Risk-benefit of continuing treatment5
Withdrawal of drug approval5
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Uncheck an issue to choose another.
| Organization | Patient experience with avacopan | Patient quality of life | Patient safety and access | Oppose withdrawal of tavneos | Retain drug market availability |
|---|---|---|---|---|---|
Vasculitis Foundation Canada AdvocacyOppose Jon Stewart, President of the Vasculitis Foundation Canada, opposes the proposed withdrawal of Avacopan for GPA and MPA | · | · |
3 organization-typed comments could not be identified.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Filter:
- Jun 29, 2026Comment from Goodman RachelleOpposeIndividual
A patient who uses Tavneos to treat a rare autoimmune disease expresses strong support for the medication, stating it saved her life and has kept her condition stable. She opposes the proposal to withdraw approval of the drug.
Read comment → - Jun 29, 2026Comment from Vasculitis Foundation CanadaOpposeAdvocacy📎 Attachment
Jon Stewart, President of the Vasculitis Foundation Canada, opposes the proposed withdrawal of Avacopan for GPA and MPA vasculitis. The organization argues that Avacopan is a significant advancement in treatment that reduces reliance on toxic glucocorticoids and highlights positive real-world evidence of its efficacy.
Read comment → - Jun 29, 2026Comment from Goodman LeahOpposeIndividual
A private individual who is the daughter of a patient expresses strong opposition to withdrawing the drug Tavneos from the market. They argue that the medication saved their mother's life and restored her kidney function following a diagnosis of Pauci-immune glomerulonephritis.
Read comment → - Jun 17, 2026Comment from Blake JoshuaOpposeIndividual
An individual patient who has seen significant quality-of-life improvements from TAVNEOS (Avacopan) argues against withdrawing its approval. They state that while some side effects exist, the medication is necessary for patients with their specific condition to feel comfortable and normal.
Read comment → - Jun 11, 2026Comment from Fleming FrancaSupportIndividual
A patient who successfully treated severe EGPA vasculitis with Tavneos argues against withdrawing the drug's approval. They share a personal testimonial regarding how the medication improved their kidney function and allowed them to reduce their dosage of Prednisone.
Read comment → - Jun 10, 2026Comment from AnonymousOpposeIndividual
A patient living with granulomatosis with polyangiitis (GPA) argues against the withdrawal of approval for Tavneos (avacopan). The commenter highlights how the medication has significantly improved their quality of life and allowed them to reduce steroid use while maintaining disease control.
Read comment → - Jun 9, 2026Comment from K CarsonOpposeIndividual
A patient currently taking TAVNEOS (Avacopan) for ANCA vasculitis argues against withdrawing the drug's approval. She shares her positive experience with the medication, noting it has allowed her to taper off steroids and improve her quality of life compared to previous treatments.
Read comment →